Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Go back to Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'

March 19, 2024 2:50 PM EDT

Evercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining a Outperform rating.

The analyst comments "With clean label in hand & an additional $600M in the bank, Madrigal is well positioned to execute on the... More